Telix Pharmaceuticals | TLX - Ebitda

Stock Price
10.13
Daily Change
0.01 0.10%
Monthly
-7.66%
Yearly
-65.22%
Q1 Forecast
10.34

Telix Pharmaceuticals reported AUD33.24M in EBITDA for its fiscal semester ending in June of 2025.





Ebitda Change Date
Cochlear AUD 292.9M 30.1M Jun/2025
CSL USD 1.96B 1.27B Jun/2025
Integral Diagnostics AUD 46.27M 3.52M Jun/2024
Mayne Pharma AUD 20.9M 5.2M Jun/2025
Medical Developments International AUD 1.78M 3.78M Dec/2024
Mesoblast USD -17.78M 17.03M Jun/2025
Neuren Pharmaceuticals AUD 176.7M 166.79M Dec/2024
Pacific Edge NZD -13.97M 332K Sep/2024
Paradigm Biopharmaceuticals AUD -5.86M 3.79M Dec/2024
Polynovo AUD 2.86M 1.12M Jun/2024
PYC Therapeutics AUD -24.29M 1.3M Jun/2025
Ramsay Health Care AUD 1.11B 84.1M Jun/2025
ResMed USD 547.48M 27.46M Dec/2025
Sonic Healthcare AUD 839.07M 51.09M Dec/2024